Creation of an Innovative Diagnostic Framework for Hepatocellular Carcinoma Employing Bioinformatics Techniques Focused on Senescence-related and Pyroptosis-related Genes

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Feb 28

PMID 40018411

Authors

Baixue Liu

Youguang Ao

Chunhui Liu

Feiyun Bai

Zhi Zhou

Juan Huang

Qi Wang

Affiliations

Soon will be listed here.

Abstract

Background: Liver hepatocellular carcinoma (LIHC) continues to pose a major global health concern and is characterized by elevated mortality rates and a lack of effective therapies. This study aimed to explore differential gene expression linked to cellular senescence and pyroptosis in LIHC and to develop a prognostic risk model for use in clinical settings.

Methods: We acquired datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). DESeq2 was used to identify differentially expressed genes associated with cell senescence and pyrodeath. The least absolute shrinkage and selection operator (LASSO) regression model was developed using cellular senescence- and pyroptosis-related differentially expressed genes (CSR&PRDEGs), and its predictive performance was evaluated with Kaplan-Meier survival analysis and time-dependent receiver operating characteristic (ROC) curves. We also performed various functional analyses of the genes. These findings were validated by real-time fluorescence quantitative polymerase chain reaction (PCR).

Results: Using bioinformatics analysis, we developed a prognostic risk framework incorporating six critical genes: , and .The model demonstrated a statistically significant difference in overall survival between the high-risk and low-risk groups (p < 0.05). Additionally, real-time fluorescence quantitative PCR confirmed that genes , and were significantly overexpressed in the peripheral blood of patients with LIHC in comparison to normal volunteers, thereby validating the prognostic risk model's accuracy.

Conclusions: This study systematically elucidated the functions of genes associated with senescence and pyroptosis in LIHC cells. The constructed prognostic risk model serves to guide the development of personalized treatment plans, enhance patient management via risk stratification, facilitate the identification of high-risk patients, intensify monitoring or implement proactive interventions, thereby providing a novel perspective for the diagnosis and treatment of LIHC.

References

Yang J, Wang C, Zhang Y, Cheng S, Xu Y, Wang Y . A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer. J Ovarian Res. 2023; 16(1):196. PMC: 10512632. DOI: 10.1186/s13048-023-01275-2. View

Bharadwaj A, Kempster E, Waisman D . The ANXA2/S100A10 Complex-Regulation of the Oncogenic Plasminogen Receptor. Biomolecules. 2021; 11(12). PMC: 8698604. DOI: 10.3390/biom11121772. View

El-Serag H . Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6):1264-1273.e1. PMC: 3338949. DOI: 10.1053/j.gastro.2011.12.061. View

Okusaka T, Ikeda M . Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO Open. 2019; 3(Suppl 1):e000455. PMC: 6307608. DOI: 10.1136/esmoopen-2018-000455. View

Shangguan F, Zhou H, Ma N, Wu S, Huang H, Jin G . A Novel Mechanism of Cannabidiol in Suppressing Hepatocellular Carcinoma by Inducing GSDME Dependent Pyroptosis. Front Cell Dev Biol. 2021; 9:697832. PMC: 8327166. DOI: 10.3389/fcell.2021.697832. View

Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C . Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH). J Clin Oncol. 2022; 41(1):117-127. DOI: 10.1200/JCO.22.00392. View

Rich J, Neely J, Paniello R, Voelker C, Nussenbaum B, Wang E . A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 2010; 143(3):331-6. PMC: 3932959. DOI: 10.1016/j.otohns.2010.05.007. View

Carambia A, Freund B, Schwinge D, Heine M, Laschtowitz A, Huber S . TGF-β-dependent induction of CD4⁺CD25⁺Foxp3⁺ Tregs by liver sinusoidal endothelial cells. J Hepatol. 2014; 61(3):594-9. DOI: 10.1016/j.jhep.2014.04.027. View

Piotrowski I, Kulcenty K, Suchorska W . Interplay between inflammation and cancer. Rep Pract Oncol Radiother. 2020; 25(3):422-427. PMC: 7191124. DOI: 10.1016/j.rpor.2020.04.004. View

10.

Jiang W, He Z, Jiang W, Du J, Yuan L, Luo C . Construction of immune cell infiltration protein network based on clinical low grade glioma cases. Front Oncol. 2022; 12:956348. PMC: 9530812. DOI: 10.3389/fonc.2022.956348. View

11.

He C, Klionsky D . Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43:67-93. PMC: 2831538. DOI: 10.1146/annurev-genet-102808-114910. View

12.

Wang S, Du X, Han X, Yang F, Zhao J, Li H . Influence of socioeconomic events on cause-specific mortality in urban Shanghai, China, from 1974 to 2015: a population-based longitudinal study. CMAJ. 2018; 190(39):E1153-E1161. PMC: 6167223. DOI: 10.1503/cmaj.180272. View

13.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

14.

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

15.

He H, Xiao L, Cheng S, Yang Q, Li J, Hou Y . Annexin A2 Enhances the Progression of Colorectal Cancer and Hepatocarcinoma via Cytoskeleton Structural Rearrangements. Microsc Microanal. 2019; 25(4):950-960. DOI: 10.1017/S1431927619000679. View

16.

Wang H, Huo X, Yang X, He J, Cheng L, Wang N . STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017; 16(1):136. PMC: 5558651. DOI: 10.1186/s12943-017-0680-1. View

17.

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

18.

Llovet J, Montal R, Sia D, Finn R . Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018; 15(10):599-616. DOI: 10.1038/s41571-018-0073-4. View

19.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

20.

Moon H, Park H, Ro S . c-Myc-driven Hepatocarcinogenesis. Anticancer Res. 2021; 41(10):4937-4946. DOI: 10.21873/anticanres.15307. View